Roche launches search for new schizophrenia treatment
The pharmaceuticals group, Roche, and the Icelandic biotechnology company, Decode Genetics, say they are to begin a drug discovery programme to find new treatments and diagnostic tests for schizophrenia.
The two companies are also to collaborate to create new drugs for the treatment of a disease which causes the narrowing of the arteries.
Decode has identified genes linked to both illnesses. Roche pays Decode for its gene discoveries and has the rights to develop the company's findings into diagnostic products and medicines.
Decode has bought exclusive access to Iceland's health records and is gathering genetic information from the country's population.
swissinfo with agencies
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at email@example.com.